Journal Watch · Science Translational Medicine · 2026

The orphan receptor GPR84 drives inflammation in Buruli ulcer development.

Together, these findings establish GPR84 as a promising target for host-directed therapeutic interventions in Buruli ulcer and its expression as a potential biomarker of lesion activity.

Foulon M, G Fraga A, Robbe-Saule M et al.Science Translational Medicine3 min readPharma relevance 60/100

DOI: 10.1126/scitranslmed.ads8681PMID: 41984933Study type: preclinical (animal / model) study

TL;DR

Together, these findings establish GPR84 as a promising target for host-directed therapeutic interventions in Buruli ulcer and its expression as a potential biomarker of lesion activity.

Key findings

  • Moreover, pharmacological inhibition of GPR84 with the antagonist PBI-4050, in combination with antibiotics, accelerated tissue repair in infected GPR84-competent mice, which was associated with attenuation of inflammatory responses.
  • Together, these findings establish GPR84 as a promising target for host-directed therapeutic interventions in Buruli ulcer and its expression as a potential biomarker of lesion activity.

What they did

Here, we found that genetic inactivation of the orphan receptor GPR84 in mice leads to spontaneous healing of ulcerative lesions, recapitulating the rare spontaneous healing observed in human Buruli ulcer. Mechanistically, <i>M. ulcerans</i> infection induced <i>Gpr84</i> expression through Toll-like receptor 2 engagement, promoting proinflammatory cytokine release through a self-amplifying loop that sustained receptor expression and inflammatory signaling.

Full abstract (original)

Background: Inflammatory responses can be of critical importance in determining both the course and outcome of infectious diseases. Buruli ulcer, a neglected tropical disease caused by <i>Mycobacterium ulcerans</i> (<i>M. ulcerans</i>), has been reported to induce both immunosuppressive and proinflammatory responses in the skin.

What they did: Here, we found that genetic inactivation of the orphan receptor GPR84 in mice leads to spontaneous healing of ulcerative lesions, recapitulating the rare spontaneous healing observed in human Buruli ulcer. Mechanistically, <i>M. ulcerans</i> infection induced <i>Gpr84</i> expression through Toll-like receptor 2 engagement, promoting proinflammatory cytokine release through a self-amplifying loop that sustained receptor expression and inflammatory signaling.

Results & conclusions: Moreover, pharmacological inhibition of GPR84 with the antagonist PBI-4050, in combination with antibiotics, accelerated tissue repair in infected GPR84-competent mice, which was associated with attenuation of inflammatory responses. Together, these findings establish GPR84 as a promising target for host-directed therapeutic interventions in Buruli ulcer and its expression as a potential biomarker of lesion activity.

Abstract © the authors / Science Translational Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1126/scitranslmed.ads8681 · PubMed 41984933.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Science Translational Medicine study find?

Together, these findings establish GPR84 as a promising target for host-directed therapeutic interventions in Buruli ulcer and its expression as a potential biomarker of lesion activity.

What type of study is this?

It is a preclinical (animal / model) study, published in Science Translational Medicine in 2026. Here, we found that genetic inactivation of the orphan receptor GPR84 in mice leads to spontaneous healing of ulcerative lesions, recapitulating the rare spontaneous healing observed in human Buruli ulcer.

Where can I read the original paper?

The original is at the publisher via DOI 10.1126/scitranslmed.ads8681. PubMed ID: 41984933. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Foulon M, G Fraga A, Robbe-Saule M et al.. The orphan receptor GPR84 drives inflammation in Buruli ulcer development.. Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.ads8681.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/the-orphan-receptor-gpr84-drives-inflammation-in-buruli-ulcer-developmen-ds8681/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides